Development of respiratory syncytial virus (RSV) vaccines for infants

Journal of Infection

Volumn 74, Issue , 2017, Pages S143-S146

  Gerretsen, Hannah E ^a   Sande, Charles J ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b KEMRI WELLCOME TRUST RESEARCH PROGRAMME   (Kenya)

Author keywords

Live attenuated vaccines; Respiratory syncytial virus; Vaccines; Virus fusion protein; Virus vectored vaccines

Indexed keywords

LIVE VACCINE; PARAINFLUENZA VACCINE; RESPIRATORY SYNCYTIAL VIRUS VACCINE; VIRUS ANTIGEN; VIRUS VECTOR;

AGE DISTRIBUTION; ARTICLE; DEATH; DISEASE SEVERITY; DRUG DESIGN; DRUG SAFETY; HUMAN; HUMAN RESPIRATORY SYNCYTIAL VIRUS; INCIDENCE; INFANT; INFECTION RISK; NONHUMAN; RESPIRATORY SYNCYTIAL VIRUS INFECTION; DRUG DEVELOPMENT; HISTORY; IMMUNOLOGY; ISOLATION AND PURIFICATION; NEWBORN; TRENDS;

DRUG DISCOVERY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; INFANT; INFANT, NEWBORN; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES;

EID: 85025836010     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/S0163-4453(17)30205-0     Document Type: Article

References (36)

1. Nair, H., Nokes, D.J., Gessner, B.D., Dherani, M., Madhi, S.A., Singleton, R.J., et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 375:9725 (2010), 1545–1555.
2. Welliver, R.C. Sr., Checchia, P.A., Bauman, J.H., Fernandes, A.W., Mahadevia, P.J., Hall, C.B., Fatality rates in published reports of RSV hospitalizations among high-risk and otherwise healthy children. Curr Med Res Opin 26:9 (2010), 2175–2181.
3. Palmer, L., Hall, C.B., Katkin, J.P., Shi, N., Masaquel, A.S., McLaurin, K.K., et al. Healthcare costs within a year of respiratory syncytial virus among Medicaid infants. Pediatr Pulmonol 45:8 (2010), 772–781.
4. O'Shea, M.K., Pipkin, C., Cane, P.A., Gray, G.C., Respiratory syncytial virus: an important cause of acute respiratory illness among young adults undergoing military training. Influenza Other Respi Viruses 1:5-6 (2007), 193–197.
5. Hall, W.J., Hall, C.B., Speers, D.M., Respiratory syncytial virus infection in adults: clinical, virologic, and serial pulmonary function studies. Ann Intern Med 88:2 (1978), 203–205.
6. Openshaw, P.J., Tregoning, J.S., Immune responses and disease enhancement during respiratory syncytial virus infection. Clin Microbiol Rev 18:3 (2005), 541–555.
7. Aherne, W., Bird, T., Court, S.D., Gardner, P.S., McQuillin, J., Pathological changes in virus infections of the lower respiratory tract in children. J Clin Pathol 23:1 (1970), 7–18.
8. Johnson, J.E., Gonzales, R.A., Olson, S.J., Wright, P.F., Graham, B.S., The histopathology of fatal untreated human respiratory syncytial virus infection. Mod Pathol 20:1 (2007), 108–119.
9. Kim, H.W., Canchola, J.G., Brandt, C.D., Pyles, G., Chanock, R.M., Jensen, K., et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 89:4 (1969), 422–434.
10. Potash, L., Tytell, A.A., Sweet, B.H., Machlowitz, R.A., Stokes, J. Jr., Weibel, R.E., et al. Respiratory virus vaccines. I. Respiratory syncytial and parainfluenza virus vaccines. Am Rev Respir Dis 93:4 (1966), 536–548.
11. Chin, J., Magoffin, R.L., Shearer, L.A., Schieble, J.H., Lennette, E.H., Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am J Epidemiol 89:4 (1969), 449–463.
12. Murphy, B.R., Prince, G.A., Walsh, E.E., Kim, H.W., Parrott, R.H., Hemming, V.G., et al. Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine. J Clin Microbiol 24:2 (1986), 197–202.
13. Murphy, B.R., Walsh, E.E., Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity. J Clin Microbiol 26:8 (1988), 1595–1597.
14. McLellan, J.S., Chen, M., Joyce, M.G., Sastry, M., Stewart-Jones, G.B., Yang, Y., et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 342:6158 (2013), 592–598.
15. McLellan, J.S., Chen, M., Leung, S., Graepel, K.W., Du, X., Yang, Y., et al. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science 340:6136 (2013), 1113–1117.
16. Killikelly, A.M., Kanekiyo, M., Graham, B.S., Pre-fusion F is absent on the surface of formalin-inactivated respiratory syncytial virus. Sci Rep, 6, 2016, 34108.
17. Ngwuta, J.O., Chen, M., Modjarrad, K., Joyce, M.G., Kanekiyo, M., Kumar, A., et al. Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera. Sci Transl Med, 7(309), 2015, 309ra162.
18. Friedewald, W.T., Forsyth, B.R., Smith, C.B., Gharpure, M.A., Chanock, R.M., Low-temperature-grown RS virus in adult volunteers. JAMA 204:8 (1968), 690–694.
19. Polack, F.P., Karron, R.A., The future of respiratory syncytial virus vaccine development. Pediatr Infect Dis J 23:1 Suppl (2004), S65–S73.
20. Kim, H.W., Arrobio, J.O., Brandt, C.D., Wright, P., Hodes, D., Chanock, R.M., et al. Safety and antigenicity of temperature sensitive (TS) mutant respiratory syncytial virus (RSV) in infants and children. Pediatrics 52:1 (1973), 56–63.
21. Murata, Y., Respiratory syncytial virus vaccine development. Clin Lab Med 29:4 (2009), 725–739.
22. Crowe, J.E. Jr., Bui, P.T., London, W.T., Davis, A.R., Hung, P.P., Chanock, R.M., et al. Satisfactorily attenuated and protective mutants derived from a partially attenuated cold-passaged respiratory syncytial virus mutant by introduction of additional attenuating mutations during chemical mutagenesis. Vaccine 12:8 (1994), 691–699.
23. Karron, R.A., Buchholz, U.J., Collins, P.L., Live-attenuated respiratory syncytial virus vaccines. Curr Top Microbiol Immunol 372 (2013), 259–284.
24. Crowe, J.E. Jr., Influence of maternal antibodies on neonatal immunization against respiratory viruses. Clin Infect Dis 33:10 (2001), 1720–1727.
25. Ambrose, C.S., Wu, X., Belshe, R.B., The efficacy of live attenuated and inactivated influenza vaccines in children as a function of time postvaccination. Pediatr Infect Dis J 29:9 (2010), 806–811.
26. Ambrose, C.S., Levin, M.J., Belshe, R.B., The relative efficacy of trivalent live attenuated and inactivated influenza vaccines in children and adults. Influenza Other Respir Viruses 5:2 (2011), 67–75.
27. Hoft, D.F., Babusis, E., Worku, S., Spencer, C.T., Lottenbach, K., Truscott, S.M., et al. Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children. J Infect Dis 204:6 (2011), 845–853.
28. Rostad, C.A., Stobart, C.C., Gilbert, B.E., Pickles, R.J., Hotard, A.L., Meng, J., et al. A Recombinant Respiratory Syncytial Virus Vaccine Candidate Attenuated by a Low-Fusion F Protein Is Immunogenic and Protective against Challenge in Cotton Rats. J Virol 90:16 (2016), 7508–7518.
29. Lambe, T., Novel viral vectored vaccines for the prevention of influenza. Mol Med 18 (2012), 1153–1160.
30. Tripp, R.A., Tompkins, S.M., Virus-vectored influenza virus vaccines. Viruses 6:8 (2014), 3055–3079.
31. Xing, Z., Lichty, B.D., Use of recombinant virus-vectored tuberculosis vaccines for respiratory mucosal immunization. Tuberculosis (Edinb) 86:3-4 (2006), 211–217.
32. Ewer, K.J., Sierra-Davidson, K., Salman, A.M., Illingworth, J.J., Draper, S.J., Biswas, S., et al. Progress with viral vectored malaria vaccines: A multi-stage approach involving “unnatural immunity”. Vaccine 33:52 (2015), 7444–7451.
33. Green, C.A., Scarselli, E., Sande, C.J., Thompson, A.J., de Lara, C.M., Taylor, K.S., et al. Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults. Sci Transl Med, 7(300), 2015, 300ra126.
34. Henao-Restrepo, A.M., Longini, I.M., Egger, M., Dean, N.E., Edmunds, W.J., Camacho, A., et al. Efficacy and effectiveness of an rVSV- vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet 386:9996 (2015), 857–866.
35. Afolabi, M.O., Tiono, A.B., Adetifa, U.J., Yaro, J.B., Drammeh, A., Nebie, I., et al. Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and Infants. Mol Ther 24:8 (2016), 1470–1477.
36. Dudek, T., Knipe, D.M., Replication-defective viruses as vaccines and vaccine vectors. Virology 344:1 (2006), 230–239.